The Trump administration is preparing to release a sweeping 195-page national drug control strategy that would deploy wastewater monitoring across the country to track illegal drug use in real time, a first-of-its-kind federal surveillance tool aimed at a crisis that killed more than 68,000 Americans in the most recent twelve-month reporting period. CBS News obtained a draft of the document, which also calls for artificial intelligence cargo screening at ports of entry, electronic health record analysis to flag overdose risk, and a prominent role for religious faith in addiction recovery.
Drug czar Sara Carter, who leads the Office of National Drug Control Policy, framed the plan in blunt terms. In a statement to CBS News, Carter said the administration views the document as more than a policy paper.
"We are taking the fight to the enemies that profit from killing our citizens. As we attack the supply of these poisons, we will work tirelessly to eradicate the demand for them in our country. This document is more than a plan; it is our pledge to secure our homeland, protect our children and families, and bring these criminals to justice."
The White House intends to release the full strategy in the coming days. What the draft reveals is a document that treats drug abuse as both a law enforcement problem and a public health emergency, and is willing to use technology, data, and even the pulpit to fight it.
The centerpiece innovation is a national wastewater-based monitoring system. The draft states that the administration will "prioritize establishing new data systems to monitor drug consumption in real-time, through a national wastewater-based monitoring system and biosurveillance." The strategy describes these as "objective measures" that would deliver "timely, localized data on current drug use and trafficking patterns."
Wastewater epidemiology is not new in concept, researchers and some municipalities have used sewer sampling to detect drug metabolites for years. But deploying it at the federal level as a standing national program would mark a significant expansion. The strategy also calls for biologic specimen testing to improve measurements of drug use trends.
The administration has already shown a willingness to intervene in wastewater infrastructure when it judges local authorities to be falling short. After a 72-inch section of the Potomac Interceptor collapsed in Maryland on January 19, approximately 243 million gallons of wastewater overflowed into the Potomac River. President Trump directed federal authorities to "immediately provide all necessary Management, Direction, and Coordination" to protect the capital region's water supply, saying it was "clear Local Authorities cannot adequately handle this calamity."
That episode underscored the administration's posture: when state and local governments fail to manage critical water systems, the federal government will step in. A national drug-monitoring network built on wastewater analysis would extend that logic into public health enforcement.
The draft strategy pushes hard on technology. Artificial intelligence would be applied to screen cargo for illicit drugs at ports of entry, a direct response to the flow of fentanyl and other synthetics that has overwhelmed traditional inspection methods. The administration has already designated certain cartels as foreign terror organizations and carried out deadly strikes on alleged drug boats in the Caribbean and Pacific.
Beyond the border, the strategy envisions AI tools examining electronic health records to "identify patients at high risk of overdose." Search algorithms would be created to detect emerging drug threats. The approach reflects a data-first mindset: rather than relying solely on after-the-fact death counts, the administration wants predictive tools that flag danger before the body count rises.
That kind of aggressive data use will inevitably raise questions about privacy. The draft, as described, does not detail what protections would govern the review of patient health records. Those details will matter. But the impulse, to use every available tool to get ahead of a crisis that has been killing tens of thousands of Americans per year, is hard to argue with on its merits.
The administration has been willing to use enforcement tools aggressively across multiple policy fronts, and this drug strategy fits that pattern.
Perhaps the most distinctive element of the strategy is its explicit embrace of faith-based addiction recovery. The draft states plainly that "secular education and treatment are important, but for those who have faith, adding God into the equation brings in a special power."
That language will draw predictable criticism from the usual corners. But the document does not mandate religious treatment. It encourages it for those who want it. The draft calls on faith leaders to "use their influence and pulpit to promote the social norm of not using drugs and bringing hope and support to those who have the treatable condition of addiction."
Anyone who has spent time around addiction recovery knows that faith-based programs, from Alcoholics Anonymous to church-run rehabilitation centers, have been part of the landscape for decades. Acknowledging their role in a federal strategy is not theocracy. It is common sense.
The strategy also supports medication-based treatment for opioid use disorder and calls for research into similar pharmacological approaches for methamphetamine, cocaine, and marijuana addiction. It says addiction care should be integrated with other medical care and describes treatment as needing to be "individualized and comprehensive." The draft argues it "should be easier to access treatment than it is to buy illicit drugs."
On harm reduction, the document takes a measured position. It says naloxone "must be as common as having epinephrine to treat an allergic reaction" and describes fentanyl test strips as an "important tool" for detecting contaminated drugs. That said, the Substance Abuse and Mental Health Services Agency recently released a letter stating that test strips cannot be purchased with federal grants, a tension within the administration's own bureaucracy that the strategy does not appear to resolve.
The draft does not limit itself to enforcement and treatment. It makes a cultural argument. The document asserts that "American society has become increasingly permissive of illicit drug use" in films, music, and public spaces. It accuses marketers of nicotine, alcohol, marijuana, and psychedelics of adopting "strategies similar to Big Tobacco's historical targeting of young audiences."
On marijuana specifically, the strategy warns that products of "unprecedented high potency" are often "aggressively advertised, and often packaged to appeal to minors." This tracks with growing concern among parents and public health researchers about the gap between the mellow branding of legal cannabis and the reality of concentrates and edibles far stronger than anything available a generation ago.
The broader White House agenda has shown a willingness to push controversial priorities through executive action and legal channels, and this strategy fits that mold, using the bully pulpit alongside enforcement mechanisms.
Yet the administration is not uniformly hostile to all controlled substances. President Trump recently signed an executive order making it easier for scientists to study psychedelics for possible mental health treatments. And earlier this month, the Justice Department announced it was ordering the rescheduling of certain marijuana products to a lower drug classification while moving to expedite the broader reclassification of marijuana.
That combination, tougher enforcement against fentanyl and cartel supply chains, openness to psychedelic research, marijuana rescheduling, and a 195-page strategy that quotes Scripture alongside data science, suggests a drug policy more layered than either side's caricature would allow.
The strategy arrives against a backdrop of mixed signals. U.S. overdose deaths were declining after peaking in mid-2023, a trend the administration can reasonably point to as evidence that tougher border enforcement and supply-side pressure are working. Federal data show over 68,000 deaths in the twelve-month period ending in November, still a staggering toll, but lower than the peak.
At the same time, the number of Americans who reported using illicit drugs in the past year ticked up in 2024, driven mostly by increased marijuana use. That divergence, fewer overdose deaths but more drug use, is exactly the kind of complexity that a serious strategy needs to address. A policy that only counts bodies misses the upstream problem. A policy that only moralizes about drug use ignores the bodies.
The administration has repeatedly demonstrated its preference for centralized federal coordination when it believes local or state efforts are inadequate, and this drug strategy extends that instinct into public health.
The draft strategy tries to hold both realities. It pairs aggressive interdiction, AI cargo screening, cartel designations, military strikes on drug boats, with treatment expansion, naloxone distribution, and faith-based recovery. Whether the bureaucracy can execute a plan this ambitious is another question entirely.
The 195-page document, once released, will face scrutiny on several fronts. Which federal agencies will run the wastewater monitoring program? What drugs will it test for? What privacy guardrails will govern the AI review of electronic health records? How will the administration reconcile its support for fentanyl test strips with its own agency's refusal to fund them through federal grants? And how will marijuana rescheduling coexist with a strategy that warns about high-potency cannabis marketed to minors?
These are legitimate questions. But they should not obscure the basic seriousness of the effort. For years, the federal response to the overdose crisis lurched between libertarian neglect and bureaucratic half-measures. This strategy, whatever its flaws, treats the problem as urgent and multi-dimensional. It deploys technology, law enforcement, medicine, and faith, and dares to say that a culture that normalizes drug use bears some responsibility for the results.
Congress will have its say. Courts may weigh in on the surveillance components. Senate Republicans have shown willingness to fund the administration's priorities when the case is made, and 68,000 dead Americans in a single year makes a case that is hard to ignore.
When it is easier to buy fentanyl than to get into a treatment program, the system has failed. A government willing to test the sewers, scan the cargo, and invite the churches to help is at least trying to fix what decades of permissiveness broke.
